Australia's Argent Biopharma surges on expanding CannEpil license to veterinary care
31/07/2026 05:18
BUZZ-Australia's Argent Biopharma surges on expanding CannEpil license to veterinary care ** Shares of Australia's Argent Biopharma RGT.AX rise as much as 75.7% to A$0.065, their highest since July 23
** Biopharmaceutical company says it has expanded the scope of its Exclusive Global Licensing Agreement for CannEpil to include veterinary applications alongside human neurological indications
** Co's CannEpil product is designed to treat drug-resistant epilepsy and cerebral palsy
** The amended licensing agreement introduces a 10% perpetual royalty for RGT for veterinary applications, with co still retaining its existing 15% perpetual royalty on future human therapeutic sales of CannEpil
** Still, shares down 28.6% YTD
(Reporting by Shruti Agarwal in Bengaluru)
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program